stockrow
Saturday 7 November 2026
Export CVM’s income statement to Excel — free account
Cel-Sci Corporation
- EPS
- +65.4%
- Free cash flow
- −2.33%
- Total debt
- −39.7%
Quarter to June 2026, against a year earlier
1.45
0.08
+5.84%
Follow CVM
Alert me
Cel-Sci Corporation (CVM) EV/Sales
As of 6 November 2026, Cel-Sci Corporation (CVM) trades at a EV/Sales of 27.6×. Over the past ten years it has ranged from 18.7× (June 2026) to 1,960× (April 2021); the current reading is higher than 3% of that period. That is above the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2020 | 833× | 35.47% |
| FY2019 | 615× | 282.96% |
| FY2018 | 161× | (6.28%) |
| FY2016 | 171× | 94.96% |
| FY2015 | 87.9× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Sep 2020 | 833× | (8.27%) |
| Jun 2020 | 908× | 13.53% |
| Mar 2020 | 800× | (8.40%) |
| Dec 2019 | 874× | 42.00% |
| 18 more quarters | Free account |
Against its own ten years
Low 18.7×
High 1,960×
Ten-year median
177×
Current reading's percentile
4
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| AARD Aardvark Therapeutics, Inc. compare | n/m |
| RNAZ TransCode Therapeutics Inc. compare | n/m |
| NXTC NextCure, Inc. compare | 0.4× |
| EVAX Evaxion A/S - Sponsored ADR compare | 1.4× |
| CELU Celularity, Inc. compare | 3.4× |
| BYSI BeyondSpring Inc. compare | 15.4× |
| IGC IGC Pharma, Inc. compare | 19.3× |
| ABVC ABVC BioPharma, Inc. compare | 20.6× |
| CVM Cel-Sci Corporation | 27.6× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)